Targeting Certain Genes With Iodine-131 Radiotherapy for Thyroid Cancer
Posted: Friday, August 14, 2020
According to research published in Disease Markers, patients with thyroid carcinoma may experience therapeutic benefit from targeted iodine-131 radiotherapy. Gao Weili, of Huzhou Central Hospital in China, and colleagues found that CDH5, KDR, CD34, FLT4, EMCN, FLT1, ROBO4, PTPRB, and CD93 were the most impactful potential gene targets for this therapy.
The study included 568 samples of thyroid carcinoma available in The Cancer Genome Atlas database; the investigators located 500 differentially expressed genes that may or may not have been subjected to iodine-131 radiotherapy. When differentially expressed genes exposed to iodine-131 radiation treatment were compared with hub module nodes, 53 hub genes were identified. A quantitative polymerase chain reaction analysis confirmed the mRNA expression of the hub genes most critical in thyroid carcinoma tissues.
Of the 500 differentially expressed genes, 167 were upregulated, and 333 were downregulated. A total of 428 nodes were found to have the strongest association with iodine-131 radiotherapy exposure. A protein-protein interaction network was created, within which CDH5, KDR, CD34, FLT4, EMCN, FLT1, ROBO4, PTPRB, and CD93 showed higher degrees and were primarily associated with vascular function. A set of nine mRNAs found in thyroid carcinoma tissues exposed to iodine-131 radiotherapy exhibited relatively lower degrees.
“In the follow-up clinical treatment, the weight of genes would be comprehensively considered,” the authors commented, “and a gene screening model based on the nine genes may be constructed to provide guidance for the selection of therapeutic options.”
Disclosure: The study authors have reported no conflicts of interest.